Book Prepares Children for BMT Procedures

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 6
Volume 9
Issue 6

A new book, Me and My Marrow: A Kid’s Guide to Bone Marrow Transplants, helps guide children with cancer through the transplant procedure. The book was inspired by 13-year-old Christina Cuzzone, of Northbrook, Illinois, who was diagnosed with leukemia at age 9 and underwent a BMT. After recovering from the transplant, Christina recognized the need for a book to help other children.

A new book, Me and My Marrow: A Kid’s Guide to Bone Marrow Transplants, helps guide children with cancer through the transplant procedure. The book was inspired by 13-year-old Christina Cuzzone, of Northbrook, Illinois, who was diagnosed with leukemia at age 9 and underwent a BMT. After recovering from the transplant, Christina recognized the need for a book to help other children.

She shared her story with a neighbor employed by Fujisawa Healthcare, Inc., a local pharmaceutical company, and the company worked with her to create the book. It is being distributed to transplant centers nationwide and on the Internet at meandmymarrow.com.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content